TauRx Therapeutics, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S. The addition of 35 clinical research centers means more patients suffering from mild or moderate Alzheimer's, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx's Alzheimer's clinical trials.
Professor Claude M. Wischik, M.D., TauRx's co-founder and chairman, said, "TauRx's treatment, LMTX, being evaluated in phase III clinical trials for Alzheimer's, will represent a breakthrough in dementia treatment if, as we hope to demonstrate, it slows and even halts the progression of the disease, as our earlier studies have shown."
"This compound is potentially a disease-modifying approach to treating Alzheimer's, targeting the tangles of tau protein that develop in the brain which are clearly linked to the progression of dementia," said Wischik. "We are pleased to expand the number of research centers conducting our clinical trial to permit more people across the U.S. to access our study.”
The main purpose of TauRx's phase III clinical research studies is to evaluate the effects of LMTX, a second generation tau aggregation inhibitor, on slowing and/or halting the progression of Alzheimer's disease. There currently is no cure for Alzheimer's, nor are there any current treatments that halt the progression of memory loss.
The expansion of study centers in the U.S. means eligible patients in Bennington, Vt.; Farmington Hills, Mich.; Waukesha, Wis.; and Creve Coeur, Mo., also will have access to study participation.